LCNDG Rapid Review: Axitinib as an option for second line advanced renal

Source: London Cancer New Drugs Group Area: Evidence > Drug Specific Reviews Axitinib (Inlyta®, Pfizer) is an orally administered multi-targeted kinase receptor inhibitor that has been licensed in the EU for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine. There are currently no treatments approved by NICE for use in people with advanced RCC who have failed to respond to prior systemic therapy. However, sunitinib and everolimus are occasionally prescribed as second-line treatments through the Cancer Drugs Fund; and are also suggested as second line treatment options in guidelines from the European Association of Urology.   No trials have compared axitinib with best supportive care. The licensing of axitinib is based on data from a phase III trial (AXIS) comparing it with sorafenib in 723 patients who have failed to respond to either sunitinib or cytokine therapy (clinical data in the temsirolimus refractory and bevacizumab with interferon-alpha refractory ...
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news